The documented prevalence of TP53 mutant variants in MDS and AML urges the development of a therapeutic approach that aims at the reactivation of mutant p53 to reinstate the wild-type p53 tumor suppression function in malignant cells. Here, TP53 is linked to myelodysplastic syndrome.